JP7165098B2 - 動脈硬化のリスクを判定する方法 - Google Patents
動脈硬化のリスクを判定する方法 Download PDFInfo
- Publication number
- JP7165098B2 JP7165098B2 JP2019081978A JP2019081978A JP7165098B2 JP 7165098 B2 JP7165098 B2 JP 7165098B2 JP 2019081978 A JP2019081978 A JP 2019081978A JP 2019081978 A JP2019081978 A JP 2019081978A JP 7165098 B2 JP7165098 B2 JP 7165098B2
- Authority
- JP
- Japan
- Prior art keywords
- snp
- genotype
- disease
- risk
- model
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims description 33
- 206010003210 Arteriosclerosis Diseases 0.000 title claims description 8
- 208000011775 arteriosclerosis disease Diseases 0.000 title claims description 8
- 239000002773 nucleotide Substances 0.000 claims description 21
- 125000003729 nucleotide group Chemical group 0.000 claims description 21
- 230000002596 correlated effect Effects 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 238000010801 machine learning Methods 0.000 claims description 3
- 210000001124 body fluid Anatomy 0.000 claims description 2
- 239000010839 body fluid Substances 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 description 90
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 90
- 210000000349 chromosome Anatomy 0.000 description 20
- 230000000052 comparative effect Effects 0.000 description 20
- 239000000523 sample Substances 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 238000007477 logistic regression Methods 0.000 description 8
- 238000003752 polymerase chain reaction Methods 0.000 description 7
- 239000013611 chromosomal DNA Substances 0.000 description 6
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000000018 DNA microarray Methods 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 102000054765 polymorphisms of proteins Human genes 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 230000013011 mating Effects 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 3
- 238000012300 Sequence Analysis Methods 0.000 description 3
- 108020004682 Single-Stranded DNA Proteins 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 229930024421 Adenine Natural products 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 238000000585 Mann–Whitney U test Methods 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 238000013528 artificial neural network Methods 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000013527 convolutional neural network Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical group CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- 101100075747 Drosophila melanogaster Lztr1 gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 238000007397 LAMP assay Methods 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000002790 cross-validation Methods 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000007637 random forest analysis Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000003765 sex chromosome Anatomy 0.000 description 1
- 238000013179 statistical model Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000012706 support-vector machine Methods 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Images
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019081978A JP7165098B2 (ja) | 2019-04-23 | 2019-04-23 | 動脈硬化のリスクを判定する方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019081978A JP7165098B2 (ja) | 2019-04-23 | 2019-04-23 | 動脈硬化のリスクを判定する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020178560A JP2020178560A (ja) | 2020-11-05 |
| JP2020178560A5 JP2020178560A5 (enrdf_load_stackoverflow) | 2022-03-22 |
| JP7165098B2 true JP7165098B2 (ja) | 2022-11-02 |
Family
ID=73022568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019081978A Active JP7165098B2 (ja) | 2019-04-23 | 2019-04-23 | 動脈硬化のリスクを判定する方法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP7165098B2 (enrdf_load_stackoverflow) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS66588B1 (sr) | 2020-10-26 | 2025-04-30 | Nippon Steel Corp | Namotano jezgro, postupak za proizvodnju namotanog jezgra i uređaj za proizvodnju namotanog jezgra |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003087360A1 (fr) | 2002-04-12 | 2003-10-23 | Osaka Industrial Promotion Organization | Procede d'evaluation du risque d'arteriosclerose, procede de mesure du risque d'arteriosclerose, microreseau, dispositif et programme pour evaluer le risque d'arteriosclerose |
| WO2005036443A1 (ja) | 2003-10-15 | 2005-04-21 | Signpost Corporation | 疾患危険度判定用遺伝子多型の決定方法、疾患危険度判定方法及び判定用アレイ |
| JP2006067903A (ja) | 2004-09-02 | 2006-03-16 | Japan Health Science Foundation | 遺伝子多型と生活習慣との組み合わせを利用した動脈硬化症のリスクの診断法 |
| WO2006126618A1 (ja) | 2005-05-26 | 2006-11-30 | Signpost Corporation | 疾患危険度判定用遺伝子多型の決定方法、疾患危険度判定方法及び判定用アレイ |
| JP2008191716A (ja) | 2007-01-31 | 2008-08-21 | Signpost Corp | 疾患リスクの提示方法およびそのプログラム |
-
2019
- 2019-04-23 JP JP2019081978A patent/JP7165098B2/ja active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003087360A1 (fr) | 2002-04-12 | 2003-10-23 | Osaka Industrial Promotion Organization | Procede d'evaluation du risque d'arteriosclerose, procede de mesure du risque d'arteriosclerose, microreseau, dispositif et programme pour evaluer le risque d'arteriosclerose |
| WO2005036443A1 (ja) | 2003-10-15 | 2005-04-21 | Signpost Corporation | 疾患危険度判定用遺伝子多型の決定方法、疾患危険度判定方法及び判定用アレイ |
| JP2006067903A (ja) | 2004-09-02 | 2006-03-16 | Japan Health Science Foundation | 遺伝子多型と生活習慣との組み合わせを利用した動脈硬化症のリスクの診断法 |
| WO2006126618A1 (ja) | 2005-05-26 | 2006-11-30 | Signpost Corporation | 疾患危険度判定用遺伝子多型の決定方法、疾患危険度判定方法及び判定用アレイ |
| JP2008191716A (ja) | 2007-01-31 | 2008-08-21 | Signpost Corp | 疾患リスクの提示方法およびそのプログラム |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020178560A (ja) | 2020-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7165098B2 (ja) | 動脈硬化のリスクを判定する方法 | |
| JP7161441B2 (ja) | 慢性副鼻腔炎のリスクを判定する方法 | |
| JP7140707B2 (ja) | 緑内障のリスクを判定する方法 | |
| JP7161442B2 (ja) | リウマチのリスクを判定する方法 | |
| JP7165617B2 (ja) | 高血圧のリスクを判定する方法 | |
| JP7165099B2 (ja) | 心筋梗塞及び／又は狭心症のリスクを判定する方法 | |
| JP7137525B2 (ja) | 接触性皮膚炎のリスクを判定する方法 | |
| JP7137520B2 (ja) | 膵炎のリスクを判定する方法 | |
| JP7137522B2 (ja) | 脊椎側弯症のリスクを判定する方法 | |
| JP7138077B2 (ja) | 卵巣がん及び／又は子宮がんのリスクを判定する方法 | |
| JP7106490B2 (ja) | 胆石のリスクを判定する方法 | |
| JP7137523B2 (ja) | じんましんのリスクを判定する方法 | |
| JP7108574B2 (ja) | アレルギー性結膜炎のリスクを判定する方法 | |
| JP7108575B2 (ja) | 難聴のリスクを判定する方法 | |
| JP7137519B2 (ja) | 結核のリスクを判定する方法 | |
| JP7137524B2 (ja) | 変形性膝関節症のリスクを判定する方法 | |
| JP7106489B2 (ja) | 脂肪肝のリスクを判定する方法 | |
| JP7160750B2 (ja) | 骨粗しょう症のリスクを判定する方法 | |
| JP7108573B2 (ja) | 慢性中耳炎のリスクを判定する方法 | |
| JP7165619B2 (ja) | 慢性気管支炎のリスクを判定する方法 | |
| JP7107882B2 (ja) | 偏頭痛のリスクを判定する方法 | |
| JP7107884B2 (ja) | 食物アレルギーのリスクを判定する方法 | |
| JP7137518B2 (ja) | 甲状腺機能亢進症のリスクを判定する方法 | |
| JP7108572B2 (ja) | 過食症のリスクを判定する方法 | |
| JP7165618B2 (ja) | アレルギー性鼻炎のリスクを判定する方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200609 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220117 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220311 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220601 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220728 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20221003 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20221021 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7165098 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |